9804 512 - 3

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 413/04, 413/14, 417/04, 417/14, A61K 31/445 — A1

(11) International Publication Number: **WO 97/30994**

(43) International Publication Date: 28 August 1997 (28.08.97)

(21) International Application Number: PCT/EP97/00525

(22) International Filing Date: 4 February 1997 (04.02.97)

(30) Priority Data:
9603755.1 22 February 1996 (22.02.96) GB

(71) Applicant *(for all designated States except GB JP US)*: PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. [BE/IE]; International Financial Services Centre, La Touche House, Dublin 1 (IE).

(71) Applicant *(for GB only)*: PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(71) Applicant *(for JP only)*: PFIZER, INC. [US/US]; 235 east 42nd Street, New York, NY 10017 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: MACKENZIE, Alexander, Roderick [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). WOOD, Anthony [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). BASS, Robert, John [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(74) Agents: WOOD, David, John et al.; Pfizer Limited, European Patents Dept., Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).


(81) Designated States: AU, BG, BR, BY, CA, CN, CZ, HU, IL, IS, JP, KR, KZ, LK, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, UZ, VN, YU, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: OXA- AND THIA-DIAZOLE MUSCARINIC RECEPTOR ANTAGONISTS

(57) Abstract

A compound of formula (I) wherein R^1 is C_1-C_6 alkyl, halo-(C_1-C_6 alkyl), C_3-C_7 cycloalkyl, C_2-C_6 alkynyl, hydroxy-(C_2-C_6 alkynyl), (C_1-C_4 alkoxy)-(C_2-C_6 alkynyl), aryl, aryl-(C_1-C_4 alkyl), heteroaryl or heteroaryl-(C_1-C_4 alkyl); R^2 is H or C_1-C_4 alkyl; R^3 is aryl, heteroaryl, 2,3-dihydrobenzofuranyl or C_4-C_7 cycloalkyl; X is O or S; and Y is a direct link, $-CH_2-$, $-(CH_2)_2-$ or $-CH_2O-$; or a pharmaceutically acceptable salt thereof. The compounds are muscarinic receptor antagonists useful in the treatment of, e.g., irritable bowel syndrome and urinary incontinence. The compounds are also useful as cognition enhancers.



(I)